Tumor Microenvironment Versus Cancer Stem Cells in Cholangiocarcinoma: Synergistic Effects?

Journal of Cellular Physiology

Volumn 231, Issue 4, 2016, Pages 768-776

  Romano, Maurizio ^a   De Francesco, Francesco ^b   Gringeri, Enrico ^a   Giordano, Antonio ^c,d   Ferraro, Giuseppe A ^b   Di Domenico, Marina ^b   Cillo, Umberto ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6 INTEGRIN; BIOLOGICAL MARKER; CD133 ANTIGEN; CD24 ANTIGEN; CYTOKERATIN 19; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; SAL LIKE PROTEIN 4; STEM CELL FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; CANCER STEM CELL; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL INTERACTION; CELL MIGRATION; CELL SURVIVAL; EARLY DIAGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEM CELL NICHE; STEM CELL SELF-RENEWAL; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; BIOLOGICAL MODEL; METABOLISM; PATHOLOGY;

BIOMARKERS, TUMOR; CHOLANGIOCARCINOMA; HUMANS; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84945278283     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25190     Document Type: Review

References (100)

1. Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF. 2007. CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointestinal Surg 11:445-451.
2. Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccio R. 2010. AISF Cholangiocarcinoma committee. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Lives Dis 42:490-495.
3. Bellizzi A, Sebastian S, Ceglia P, Centonze M, Divella R, Manzillo EF, Azzariti A, Silvestris N, Montemurro S, Callandro C, De Luca R, Cicero G, Rizzo S, Russo A, Quaranta M, Simone G, Paradiso A. 2013. Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis. J Cell Physiol 228:408-415.
4. Boonjaraspinyo S, Boonmars T, Wu Z, Loilome W, Sithithaworn P, Nagano I, Pinlaor S, Yongvanit P, Nielsen PS, Pairojkul C, Khuntikeo N. 2012. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. Tumour Biol 33:1785-1802.
5. Borovski T, De Sousa E, Melo F, Vermeulen L, Medema JP. 2011. Cancer stem cell niche: The place to be. Cancer Res 71:634-639.
6. Boulter J, Guest RV, Kendall TJ, Wilson DH, Wojtacha D, Robson AJ, Ridgway RA, Samuel K, Van Rooijen N, Barry ST, Wigmore SJ, Sanspm OJ, Forbes SJ. 2015. WNT signalling drives cholangiocarcinoma growth and can be pharmacologically inhibited. J Clin Invest 125:1269-1285.
7. Camerlingo R, Ferraro GA, De Francesco F, Romano M, Nicoletti G, Di Bonito M, Rinaldo M, D'Andrea F, Pirozzi G. 2014. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer. Oncol Rep 31:1127-1132.
8. Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, Gentile R, Alvaro D. 2010. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol 2:407-416.
9. Carrion B, Kong YP, Kaigler D, Putnam AJ. 2013. Bone marrow-derived mesenchymal stem cells enhance angiogenesis via their α6β1 integrin receptor. Exp Cell Res 319:2964-2976.
10. Chen Y, Ma L, He Q, Zhang S, Zhang C, Jia W. 2015. TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma. Biol Res 48:26.
11. Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, Miyoshi H, Nakano M, Zen Y, Nakanuma Y, Nakauchi H, Iwama A, Taniguchi H. 2007. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 133:937-950.
12. Chieffi P, Chieffi S. 2013. Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: An overview. J Cell Physiol 228:1641-1646.
13. Chowdhury I, Thompson WE, Thomas K. 2014. Prohibitins role in cellular survival through Ras-Raf-MEK-ERK pathway. J Cell Physiol 229:998-1004.
14. Cioffi M, D'Alterio C, Camerlingo R, Tirino V, Consales C, Riccio A, Ieranò C, Cecere SC, Losito NS, Greggi S, Pignata S, Pirozzi G, Scala S. 2015. Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer. Sci Rep 5:103574.
15. de Boer CJ, van Krieken JH, Janssen-van Rhijn. 1999. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 188:201-206.
16. Ding YB, Deng B, Huang YS, Xiao WM, Wu J, Zhang YQ, Wu DC, Lu GT, Wu KY. 2013. A high level of integrin α6 expression in human intrahepatic cholangiocarcinoma cells is associated with a migratory and invasive phenotype. Dig Dis Sci 58:1627-1635.
17. Elsharkawy AM, Mann DA. 2007. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46:590-597.
18. Fan L, He F, Liu H, Zhu J, Liu Y, Yin Z, Wang L, Guo Y, Wang Z, Yan Q, Huang G. 2011. CD133: A potential indicator for differentiation and prognosis of human cholangiocarcinoma. BMC Cancer 11:320.
19. Gao C, Kong NR, Chai L. 2011. The role of stem cell factor SALLA4 in leukemogenesis. Crit Rev Oncog 16:117-127.
20. Gao MQ, Choi YP, Kang S, Youn JH, Cho NH. 2010. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29:2672-2680.
21. Gores GJ. 2003. Cholangiocarcinoma: Current concepts and insights. Hepatology 37:961-969.
22. Gu MJ, Jang BI. 2014. Clinicopathologic significance of Sox2, CD44 and CD44v6 expression in intrahepatic cholangiocarcinoma. Pathol Oncol Res 20:655-660.
23. Herold-Mende C, Mock A. 2014. Microenvironment and brain tumor stem cell maintenance: Impact of the niche. Anticancer Agents Med Chem 14:1065-1074.
24. Iwakashi S, Utsunomiya T, Shimada M, Saito Y, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Bando Y. 2013. High expression of cancer stem cell markers in cholangiolocellular carcinoma. Surg Today 43:654-660.
25. Jiao XL, Zhao C, Niu M, Chen D. 2013. Downregulation of CD24 inhibits invasive growth, facilitates apoptosis and enhances chemosensitivity in gastric cancer AGS cells. Eur Rev Med Pharmacol Sci 17:1709-1715.
26. Keeratichamroen S, Leelawat K, Thongtawee T, Narong S, Aegem U, Tujinda S, Praditphol N, Tohtong R. 2011. Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival. Int J Oncol 39:873-881.
27. Kim K, Min HS, Chie EK, Jang JY, Kim SW, Han SW, Oh DY, Im SA, Kim TY, Bang YJ, Jang JJ, Ha SW. 2013. CD24 expression predicts distant metastasis in extrahepatic bile duct cancer. World J Gastroenterol 19:1438-1443.
28. Kim Y, Kim MO, Shin JS, Park SH, Kim SB, Kim J, Park SC, Han CJ, Ryu JK, Yoon YB, Kim YT. 2014. Hedgehog signaling between cancer stem cells and hepatic stellate cells in promoting cholangiocarcinoma. Ann Surg Oncol 21:2684-2698.
29. Kokuryo T, Yokoyama Y, Nagino M. 2012. Recent advances in cancer stem cell research for cholangiocarcinoma. J Hepatobiliary Pancreat Sci 19:606-613.
30. Komori J, Marusawa H, Machimoto T, Endo Y, Kinoshita K, Kou T, Haga H, Ikai I, Uemoto S, Chiba T. 2008. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 47:888-896.
31. Kuhn NZ, Tuan RS. 2010. Regulation of stemness and stem cell niche of mesenchymal stem cells: Implications in tumorigenesis and metastasis. J Cell Physiol 222:268-277.
32. Kunlabut K, Vaeteewoottacham K, Wongkham C, Khuntikeo N, Waraasawapati S, Pairojkul C, Wongkham S. 2012. Aberrant expression of CD44 in bile duct cancer correlates with poor prognosis. Asian Pac J Cancer Prev 13 Suppl:95-99.
33. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. 2014. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014:149185.
34. Lee KT, Liu TS. 2003. Expression of transforming growth factor betas and their signalling receptors in stone-containing intrahepatic bile ducts and cholangiocarcinoma. World J Surg 27:1143-1148.
35. Leelawat K, Keeratichamroen S, Leelawat S, Tohtong R. 2013. CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2. Oncol Lett 6:1439-1446.
36. Leelawat K, Thongtawee T, Narong S, Subwongcharoen S, Treepongkaruna SA. 2011. Strong expression of C133 is associated with increased cholangiocarcinoma progression. World J Gastroenterol 17:1192-1198.
37. Lennartsson J, Ronnstrand L. 2012. Stem cell factor receptor/c-kit: From basic science to clinical implications. Physiol Rev 92:1619-1649.
38. Li A, Jiao Y, Yong KJ, Wang F, Gao C, Yan B, Srivastava S, Lim GS, Tang P, Yang H, Tenen DG, Chai L. 2015. SALL4 is a new target in endometrial cancer. Oncogene 34:63-72.
39. Liu H, Lv L, Yang K. 2015. Chemotherapy targeting cancer stem cells. Am J Cancer Res 5:880-893.
40. Lobo NA, Shimono Y, Qian D, Clarke MF. 2007. The biology of cancer stem cells. Annu Rev Cell Dev Biol 23:675-699.
41. Ma J, Frank MH. 2010. Tumor initiation in human malignant melanoma and potential cancer therapies. Anticancer Agents Med Chem 10:131-136.
42. Maemura K, Natsugoe S, Takao S. 2014. Molecular mechanism of cholangiocarcinoma carcinogenesis. J Hepatobiliary Pancreat Sci 21:754-760.
43. Mansuroglu T, Baumhoer D, Dudas J, Haller F, Cameron S, Lorf T, Fuzesi L, Ramadori G. 2009a. Expression of stem cell factor receptor c-kit in human nontumoral and tumoral hepatic cells. Eur J Gastroenterol Hepatol 21:1206-1211.
44. Mansuroglu T, Ramadori P, Dudas J, Malik I, Hammerich K, Fuzesi L, Ramadori G. 2009b. Lab Invest 89:562-574.
45. Meng F, Francis H, Glaser S, Han Y, DeMorrow S, Stokes A, Staloch D, Venter J, White M, Ueno Y, Reid LM, Alpini G. 2012. Role of stem cell factor and granulocyte colony-stimulating factor in remodelling during liver regeneration. Hepatology 55:209-221.
46. Mon NN, Koruryo T, Hamaguchi M. 2009. Inflammation and tumor progression: A lesson from TNF-alpha-dependent FAK signalling in cholangiocarcinoma. Methods Mol Biol 512:279-293.
47. Neuzillet C, Hammel P, Tijeras-Raballand A, Couvelard A, Raymond E. 2013. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma. Cancer Metastasis Rev 32:147-162.
48. Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, Wang XW, Reid LM, Nakauchi H. 2013. Sal-like protein 4 (SALLA4), a stem cell biomarker in liver cancers. Hepatology 57:1469-1483.
49. Oishi N, Yamashita T, Kaneko S. 2014. Molecular biology of liver cancer stem cells. Liver Cancer 3:71-84.
50. Olnes MJ, Erlich R. 2004. A review and update on cholangiocarcinoma. Oncology 66:167-179.
51. Omenetti A, Choi S, Michelotti G, Diehl AM. 2011. Hedgehog signalling in the liver. J Hepatol 54:366-373.
52. Omenetti A, Diehl AM. 2011. Hedgehog signaling in cholangiocytes. Curr Opin Gastroenterol 27:268-275.
53. Orian-Rousseau V. 2015. CD44 acts as a signaling platform controlling tumor progression and metastasis. Front Immunol 6:154.
54. Patel T. 2002. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2:10.
55. Penfornis P, Cai DZ, Harris MR, Walker R, Licini D, Fernandes JD, Orr G, Koganti T, Hicks C, Induru S, Meyer MS, Khokha R, Barr J, Pochampally RR. 2014. High CD49f expression is associated with osteosarcoma tumor progression: A study using patient-derived primary cell cultures. Cancer Med 3:796-811.
56. Pirozzi G, Tirino V, Camerlingo R, La Rocca A, Martucci N, Scognamiglio G, Franco R, Cantile M, Normanno N, Rocco G. 2013. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer. Oncol Rep 29:1763-1768.
57. Pongcharoen P, Jinawath A, Tohtong R. 2011. Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells. Clin Exp Metastasis 28:827-839.
58. Rad SM, Bamdad T, Sadeghizadeh M, Arefian E, Lotfinia M, Ghanipour M. 2015. Transcription factor decoy against stem cells master regulators, Nanog and Oct-4: A possible approach for differentiation therapy. Tumor Biol 36:2621-2629.
59. Reya T, Morrison SJ, Clarke MF, Weissmann IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414:105-111.
60. Romano M, De Francesco F, Pirozzi G, Gringeri E, Boetto R, Di Domenico M, Zavan B, Ferraro GA, Cillo U. 2015. Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience 2:443-456.
61. Rybak AP, Bristow RG, Kapoor A. 2015. Prostate cancer stem cells: Deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget 6:1900-1919.
62. Santarpia L, Lippman SM, El-Naggar AK. 2012. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:103-119.
63. Sato Y, Harada K, Itasu K, Ikeda H, Kakuda Y, Shimomura S, Shan Ren, Sasaki N, Nakamura M. 2010. Epithelial-mesenchymal transition induced by transforming growth factor-íbetaý1/Snail activation aggravates invasive growth of cholangiocarcinoma. Am J Pathol 177:141-152.
64. Saxena R, Theise N. 2004. Canals of Hering: Recent insights and current knowledge. Semin Liver Dis 24:43-48.
65. Scadden DT. 2006. The stem-cell niche as an entity of action. Nature 441:1075-1079.
66. Schmitz KJ, Lang H, Wohlschlaeger J, Sotiropoulos GC, Reis H, Schmid KW, Baba HA. 2007. AKT and ERK 1/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol 13:6470-6477.
67. Shaib Y, El-Serag HB. 2004. The epidemiology of cholangiocarcinoma. Semin Liver Dis 24:115-125.
68. Shang B, Zhang G, Pan Y, Zhou Q. 2012. Deciphering the key features of malignant tumor microenvironment for anti-cancer therapy. Cancer Microenviron 5:211-223.
69. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, Ikemoto T. 2010. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol 45:896-902.
70. Shuang ZY, Wu WC, Xu J, Liu YC, Lao XM, Zheng L, Li S. 2014. Transforming growth factor-β1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Cancer Lett 354:320-328.
71. Siegel R, Ma J, Zou Z, Jemal A. 2014. Cancer statistics, 2014. CA Cancer J Clin 64:9-29.
72. Smadja DM, Guerin CL, Boscolo E, Bieche I, Mulliken JB, Bischoff J. 2014. α6 integrin is required for the adhesion and vasculogenic potential of hemangioma stem cells. Stem Cells 32:684-693.
73. Steiner PE. 1957. Carcinoma of the liver in the United States. Acta Unio Int Contra Cancrum 13:628-645.
74. Steiner PE, Higginson J. 1959. Cholangiolocellular carcinoma of the liver. Cancer 12:753-759.
75. Su MC, Hsu C, Kao HL, Jeng YM. 2006. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett 235:34-39.
76. Sulpice L, Rayal M, Turlin B, Boucher E, Bellaud P, Desille M, Meunier B, Clement B, Boudjema K, Coulouam C. 2014. Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma. J Surg Res 192:117-123.
77. Sun Q, Li J, Wang G, Xie Y. 2014. Role of the embryonic protein SOX2 in cholangiocarcinoma. Cell Biochem Biophys 70:1311-1316.
78. Taguchi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Kojiro M. 1996. A Clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol 11:758-764.
79. Tam WL, Weinberg RA. 2013. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 19:1438-1449.
80. Tanase CP, Neagu Al, Necula LG, Mambet C, Enciu AM, Calenic B, Cruceru ML, Albulescu R. 2014. Cancer stem cells: Involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics. World J Gastroenterol 20:10790-10801.
81. Techasen A, Namwat N, Loilome W, Bungkanjana P, Khuntikeo N, Puapairoj A, Jearanaikoon P, Saya H, Yongvanit P. 2012. Tumor necrosis factor-α (TNF-α) stimulates the epithelial-mesenchymal transition regulator Snail in cholangiocarcinoma. Med Oncol 29:3091.
82. Techasen A, Namwat N, Loilome W, Duangkumpha K, Puapairoj A, Saya H, Yongvanit P. 2014. Tumor necrosis factor-α modulates epithelial mesenchymal transition mediators ZEB2 and S100A4 to promote cholangiocarcinoma progression. J Hepatobiliary Pancreat Sci 21:703-711.
83. Thanan R, Pairojkul C, Pinlaor S, Khuntikeo N, Wongkham C, Sripa B, Ma N, Vaeteewoottacham K, Furukawa A, Kobayashi H, Hiraku Y, Oikawa S, Kawanishi S, Yongvanit P, Murata M. 2013. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. Free Radic Biol Med 65:1464-1472.
84. Tickoo SK, Zee SY, Obiekwe S, Xiao H, Koea J, Robiou C, Blumgart LH, Jarnagin W, Ladanyi M, Klimstra DS. 2002. Combined hepatocellular-cholangiocarcinoma: A histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol 26:989-997.
85. Tirino V, Desiderio V, d'Aquino R, De Francesco F, Pirozzi G, Graziano A, Galderisi U, Cavaliere C, De Rosa A, Papaccio G, Giordano A. 2008. Detenction and characterization of CD133+ cancer stem cells in human solid tumours. PLoS ONE 3:e3469.
86. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G. 2013. Cancer stem cells in solid tumors: An overview and new approach for their isolation and characterization. FASEB J 27:13-24.
87. Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M, Shimizu Y, Itamoto T, Arihiro K, Okajima M, Asahara T. 2005. Immunohistochemical and mutational analyses of Wnt signalling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol 27:973-980.
88. Wang T, You N, Tao K, Wang X, Zhao G, Xia N, Li N, Tang L, Liu W, Dou K. 2012. Notch is the key factor in the process of fetal liver stem/progenitor cells differentiation into hepatocytes. Dev Growth Differ 54:605-617.
89. Weichert W, Denkert C, Burkhardt M, Gansukt Bellach, Dietel P, Kristiansen M. 2005. Cytoplasmic CD24 expression in colonrectal cancer independently correlates with shortened patient survival. Clin Cancer Res 11:6574-6581.
90. Whittaker S, Marais R, Zhu AX. 2010. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29:4989-5005.
91. Wiedmann MW, Mossner J. 2010. Molecular targeted therapy of biliary tract cancer-results of the first clinical studies. Curr Drug Targets 11:834-850.
92. Williams K, Motiani K, Giridhar PV, Kasper S. 2013. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre) metastatic niches. Exp Biol Med (Maywood) 238:324-338.
93. Wu WR, Shi XD, Zhang R, Zhu MS, Xu LB, Yu XH, Zeng H, Wang J, Liu C. 2014. Clinicopathological significance of aberrant Notch receptors in intrahepatic cholangiocarcinoma. Int J Clin Exp Pathol 7:3272-3279.
94. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, Reid LM, Minato H, Honda M, Kaneko S, Tang ZY, Wang XW. 2009. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136:1012-1024.
95. Yang S, Zheng J, Ma Y, Zhu H, Xu T, Dong K, Xiao X. 2012. Oct4 and Sox2 are overexpressed in human neuroblastoma and inhibited by chemotherapy. Oncol Rep 28:186-192.
96. Zender S, Nickeleit I, Wuestefeld T, Sorensen I, Dauch D, Bozko P, El-Khatib M, Geffers R, Bektas H, Manns MP, Gossler A, Wilkens L, Plentz R, Zender L, Malek NP. 2013. A critical role for notch signalling in the formation of cholangiocellular carcinomas. Cancer Cell 23:784-795.
97. Zhang KS, Zhou Q, Wang YF, Liang LJ. 2013. Inhibition of Wnt signalling induces cell apoptosis and suppresses cell proliferation in cholangiocarcinoma cells. Oncol Rep 30:1430-1438.
98. Zhang J, Jiao J, Cermelli S, Muir K, Jung KH, Zou R, Rashid A, Gagea M, Zabludoff S, Kalluri R, Beretta L. 2015. MiR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24+ progenitor cells. Cancer Res 75:1859-1867.
99. Zhang S, Cui W. 2014. Sox2, a key factor in the regulation of pluripotency and neural differentiation. World J Stem Cells 6:305-311.
100. Zhong C, Wu JD, Fang MM, Pu LY. 2015. Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: A meta-analysis. Tumor Biol Apr 29 Doi:10.1007/s13277-015-3487-y